This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Climo, M. W.
Right arrow Articles by Archer, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Climo, M. W.
Right arrow Articles by Archer, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1355-1360, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis

Michael W. Climo,1,* Roberto L. Patron,1 Beth P. Goldstein,2 and Gordon L. Archer1,3

Department of Internal Medicine1 and Microbiology/Immunology,3 Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, Virginia, and AMBI, Inc., Tarrytown, New York2

Received 2 January 1998/Returned for modification 5 March 1998/Accepted 25 March 1998

The emergence of clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted a search for new and novel therapeutic agents active against S. aureus. Lysostaphin, a peptidase produced by Staphylococcus simulans, specifically cleaves the glycine-glycine bonds unique to the interpeptide cross-bridge of the S. aureus cell wall. The effectiveness of various regimens of dosing with intravenous lysostaphin was compared to that of vancomycin in the rabbit model of aortic valve endocarditis caused by a clinical methicillin-resistant S. aureus isolate. All animals were treated for a total of 3 days. The most active regimen, lysostaphin given three times daily, produced sterile vegetations in 10 of 11 treated rabbits, with a mean reduction in vegetation bacterial counts of 8.5 log10 CFU/g compared to the counts in the untreated controls. In contrast, vancomycin given twice daily sterilized no vegetations and reduced vegetation bacterial counts by only 4.8 log10 CFU/g. Lysostaphin given once daily was less effective, reducing mean vegetation bacterial counts by only 3.6 log10 CFU/g, but the combination of lysostaphin once daily and vancomycin twice daily reduced the mean vegetation bacterial density by 7.5 log10 CFU/g, a result that was significantly better than that for either regimen alone (P < 0.05). Lysostaphin was well tolerated by the rabbits, with no evidence of immunological reactions following up to 9 weeks of intravenous administration. We conclude that lysostaphin given alone or in combination with vancomycin is more effective in the treatment of experimental methicillin-resistant S. aureus aortic valve endocarditis than vancomycin alone.

* Corresponding author. Mailing address: McGuire Veterans Affairs Medical Center, 1201 Broad Rock Blvd., Section 111-C, Richmond, VA 23249. Phone: (804) 675-5018. Fax: (804) 675-5437. E-mail: CLIMO.MICHAEL{at}RICHMOND.VA.GOV or MCLIMO{at}GEMS.VCU.EDU.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1355-1360, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Francius, G., Domenech, O., Mingeot-Leclercq, M. P., Dufrene, Y. F. (2008). Direct Observation of Staphylococcus aureus Cell Wall Digestion by Lysostaphin. J. Bacteriol. 190: 7904-7909 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Chanturiya, T., Mond, J. J. (2007). Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 60: 1051-1059 [Abstract] [Full Text]  
  • Oluola, O., Kong, L., Fein, M., Weisman, L. E. (2007). Lysostaphin in Treatment of Neonatal Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 51: 2198-2200 [Abstract] [Full Text]  
  • Kusuma, C., Jadanova, A., Chanturiya, T., Kokai-Kun, J. F. (2007). Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo. Antimicrob. Agents Chemother. 51: 475-482 [Abstract] [Full Text]  
  • Yang, X.-Y., Li, C.-R., Lou, R.-H., Wang, Y.-M., Zhang, W.-X., Chen, H.-Z., Huang, Q.-S., Han, Y.-X., Jiang, J.-D., You, X.-F. (2007). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 56: 71-76 [Abstract] [Full Text]  
  • Qin, Z., Yang, X., Yang, L., Jiang, J., Ou, Y., Molin, S., Qu, D. (2007). Formation and properties of in vitro biofilms of ica-negative Staphylococcus epidermidis clinical isolates. J Med Microbiol 56: 83-93 [Abstract] [Full Text]  
  • Fox, P. M., Lampen, R. J., Stumpf, K. S., Archer, G. L., Climo, M. W. (2006). Successful Therapy of Experimental Endocarditis Caused by Vancomycin-Resistant Staphylococcus aureus with a Combination of Vancomycin and {beta}-Lactam Antibiotics.. Antimicrob. Agents Chemother. 50: 2951-2956 [Abstract] [Full Text]  
  • Grundling, A., Missiakas, D. M., Schneewind, O. (2006). Staphylococcus aureus Mutants with Increased Lysostaphin Resistance.. J. Bacteriol. 188: 6286-6297 [Abstract] [Full Text]  
  • Borysowski, J., Weber-Dabrowska, B., Gorski, A. (2006). Bacteriophage endolysins as a novel class of antibacterial agents.. Exp. Biol. Med. 231: 366-377 [Abstract] [Full Text]  
  • Lu, J. Z., Fujiwara, T., Komatsuzawa, H., Sugai, M., Sakon, J. (2006). Cell Wall-targeting Domain of Glycylglycine Endopeptidase Distinguishes among Peptidoglycan Cross-bridges. J. Biol. Chem. 281: 549-558 [Abstract] [Full Text]  
  • Kusuma, C. M., Kokai-Kun, J. F. (2005). Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3256-3263 [Abstract] [Full Text]  
  • Shah, A., Mond, J., Walsh, S. (2004). Lysostaphin-Coated Catheters Eradicate Staphylococccus aureus Challenge and Block Surface Colonization. Antimicrob. Agents Chemother. 48: 2704-2707 [Abstract] [Full Text]  
  • Barequet, I. S., Ben Simon, G. J., Safrin, M., Ohman, D. E., Kessler, E. (2004). Pseudomonas aeruginosa LasA Protease in Treatment of Experimental Staphylococcal Keratitis. Antimicrob. Agents Chemother. 48: 1681-1687 [Abstract] [Full Text]  
  • Myhre, A. E., Stuestol, J. F., Dahle, M. K., Overland, G., Thiemermann, C., Foster, S. J., Lilleaasen, P., Aasen, A. O., Wang, J. E. (2004). Organ Injury and Cytokine Release Caused by Peptidoglycan Are Dependent on the Structural Integrity of the Glycan Chain. Infect. Immun. 72: 1311-1317 [Abstract] [Full Text]  
  • Wu, J. A., Kusuma, C., Mond, J. J., Kokai-Kun, J. F. (2003). Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces. Antimicrob. Agents Chemother. 47: 3407-3414 [Abstract] [Full Text]  
  • von Eiff, C., Kokai-Kun, J. F., Becker, K., Peters, G. (2003). In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood. Antimicrob. Agents Chemother. 47: 3613-3615 [Abstract] [Full Text]  
  • Chiang, F.-Y., Climo, M. (2003). Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 3002-3004 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Walsh, S. M., Chanturiya, T., Mond, J. J. (2003). Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model. Antimicrob. Agents Chemother. 47: 1589-1597 [Abstract] [Full Text]  
  • Walsh, S., Shah, A., Mond, J. (2003). Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol. Antimicrob. Agents Chemother. 47: 554-558 [Abstract] [Full Text]  
  • Dajcs, J. J., Thibodeaux, B. A., Girgis, D. O., Shaffer, M. D., Delvisco, S. M., O'Callaghan, R. J. (2002). Immunity to Lysostaphin and Its Therapeutic Value for Ocular MRSA Infections in the Rabbit. IOVS 43: 3712-3716 [Abstract] [Full Text]  
  • Kiri, N., Archer, G., Climo, M. W. (2002). Combinations of Lysostaphin with {beta}-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46: 2017-2020 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Carey, R. B., Daum, R. S. (2001). Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 48: 617-625 [Abstract] [Full Text]  
  • Climo, M. W., Ehlert, K., Archer, G. L. (2001). Mechanism and Suppression of Lysostaphin Resistance in Oxacillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 1431-1437 [Abstract] [Full Text]  
  • Dajcs, J. J., Hume, E. B. H., Moreau, J. M., Caballero, A. R., Cannon, B. M., O’Callaghan, R. J. (2000). Lysostaphin Treatment of Methicillin-Resistant Staphylococcus aureus Keratitis in the Rabbit. IOVS 41: 1432-1437 [Abstract] [Full Text]  
  • Backo, M., Gaenger, E., Burkart, A., Chai, Y. L., Bayer, A. S. (1999). Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam. Antimicrob. Agents Chemother. 43: 2565-2568 [Abstract] [Full Text]  
  • Climo, M. W., Patron, R. L., Archer, G. L. (1999). Combinations of Vancomycin and beta -Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin. Antimicrob. Agents Chemother. 43: 1747-1753 [Abstract] [Full Text]  
  • Patron, R. L., Climo, M. W., Goldstein, B. P., Archer, G. L. (1999). Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin. Antimicrob. Agents Chemother. 43: 1754-1755 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»